Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI

Molecular Imaging and Biology

Volumn 13, Issue 5, 2011, Pages 1011-1019

  Herrmann, Ken ^a   Bundschuh, Ralph A ^a   Rosenberg, Robert ^a   Schmidt, Stefan ^a   Praus, Christine ^a   Souvatzoglou, Michael ^a   Becker, Karen ^a   Schuster, Tibor ^a   Essler, Markus ^a   Wieder, Hinrich A ^a   Friess, Helmut ^a   Ziegler, Sibylle I ^a   Schwaiger, Markus ^a   Krause, Bernd J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

FDG PET; PET CT; Rectum cancer; Therapy monitoring; Therapy response

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; INTERRATER RELIABILITY; MALE; METABOLIC PARAMETERS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM ANTERIOR RESECTION; RECTUM CANCER; STANDARD UPTAKE VALUE; TREATMENT RESPONSE; VOLUMETRY;

FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; RECTAL NEOPLASMS; ROC CURVE;

EID: 84855648902     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0383-0     Document Type: Article

References (46)

1. Souvatzoglou M, Ziegler SI, Martinez MJ et al (2007) Standardised uptake values from PET/CT images: Comparison with conventional attenuation-corrected PET. Eur J Nucl Med Mol Imaging 34(3):405-412 (Pubitemid 46295346)
2. Stahl A, Ott K, Schwaiger M, Weber WA (2004) Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 31(11):1471-1478
3. Weber WA, Figlin R (2007) Monitoring cancer treatment with PET/CT: Does it make a difference? J Nucl Med 48(Suppl 1):36S-44S (Pubitemid 47604941)
4. Weber WA, Wieder H (2006) Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 33(Suppl 1):27-37
5. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M (1999) Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40(11):1771-1777 (Pubitemid 29523568)
6. Ott K, Herrmann K, Lordick F et al (2008) Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: Longterm results of a prospective study. Clin Cancer Res 14(7):2012-2018 (Pubitemid 351551110)
7. Ott K, Weber WA, Lordick F et al (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24(29):4692-4698 (Pubitemid 46646244)
8. Weber WA, Ott K, Becker K et al (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19(12):3058-3065 (Pubitemid 32565444)
9. Lammertsma AA, Hoekstra CJ, Giaccone G, Hoekstra OS (2006) How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging 33(Suppl 1):16-21
10. Lordick F, Ruers T, Aust DE et al (2008) European organisation of research and treatment of cancer (EORTC) gastrointestinal group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer 44(13):1807-1819
11. Shankar LK, Hoffman JM, Bacharach S et al (2006) Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in national cancer institute trials. J Nucl Med 47(6):1059-1066 (Pubitemid 46939960)
12. Minn H, Zasadny KR, Quint LE, Wahl RL (1995) Lung cancer: Reproducibility of quantitative measurements for evaluating 2-[F-18]- fluoro-2-deoxy-D-glucose uptake at PET. Radiology 196(1):167-173
13. Shankar LK, Sullivan DC (2007) PET/CT in cancer patient management. Commentary. J Nucl Med 48(Suppl 1):1S
14. Avril N, Rose CA, Schelling M et al (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. J Clin Oncol 18(20):3495-3502
15. Ott K, Sendler A, Becker K et al (2003) Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: A prospective phase II study. Gastric Cancer 6(3):159-167 (Pubitemid 37221566)
16. Schelling M, Avril N, Nahrig J et al (2000) Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18(8):1689-1695 (Pubitemid 30220547)
17. Weber WA, Petersen V, Schmidt B et al (2003) Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21(14):2651-2657 (Pubitemid 46606307)
18. Wieder HA, Brucher BL, Zimmermann F et al (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22(5):900-908 (Pubitemid 41103602)
19. Larson SM, Erdi Y, Akhurst T et al (1999) Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 2(3):159-171
20. Rosenberg R, Herrmann K, Gertler R et al (2009) The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis 24(2):191-200
21. Becker K, Mueller JD, Schulmacher C et al (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521-1530 (Pubitemid 37151509)
22. Martinez MJ, Bercier Y, Schwaiger M, Ziegler SI (2006) PET/CT Biograph Sensation 16. Performance improvement using faster electronics. Nuklearmedizin 45(3):126-133 (Pubitemid 44047833)
23. Ott K, Fink U, Becker K et al (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: Results of a prospective trial. J Clin Oncol 21(24):4604-4610 (Pubitemid 46594034)
24. Ott K, Vogelsang H, Marton N et al (2006) The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer. Int J Cancer 119(12):2885-2894 (Pubitemid 44846241)
25. Weber WA (2006) Positron emission tomography as an imaging biomarker. J Clin Oncol 24(20):3282-3292 (Pubitemid 46622068)
26. Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355(11):1114-1123 (Pubitemid 44394918)
27. Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345(9):638-646
28. Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (17):1731-1740
29. Calvo FA, Domper M, Matute R et al (2004) 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 58(2):528-535 (Pubitemid 38142480)
30. Cascini GL, Avallone A, Delrio P et al (2006) 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 47(8):1241-1248 (Pubitemid 47544874)
31. de Geus-Oei LF, van Laarhoven HW, Visser EP et al (2008) Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 19(2):348-352 (Pubitemid 351201718)
32. Findlay M, Young H, Cunningham D et al (1996) Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil. J Clin Oncol 14 (3):700-708 (Pubitemid 26085512)
33. Funaioli C, Pinto C, Di Fabio F et al (2007) 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy. Tumori 93(6):611-615 (Pubitemid 351158075)
34. Guillem JG, Moore HG, Akhurst T et al (2004) Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: A means for determining longterm outcomes of rectal cancer. J Am Coll Surg 199(1):1-7 (Pubitemid 38813288)
35. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA (2004) Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: A simulation study. J Nucl Med 45(9):1519-1527 (Pubitemid 47618506)
36. Krak NC, Boellaard R, Hoekstra OS, Twisk JW, Hoekstra CJ, Lammertsma AA (2005) Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging 32(3):294-301 (Pubitemid 40562120)
37. Benz MR, Allen-Auerbach MS, Eilber FC et al (2008) Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med 49 (10):1579-1584
38. Benz MR, Evilevitch V, Allen-Auerbach MS et al (2008) Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: Interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med 49(7):1038-1046 (Pubitemid 351948010)
39. Roedl JB, Halpern EF, Colen RR, Sahani DV, Fischman AJ, Blake MA (2009) Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Mol Imaging Biol 11(1):54-60
40. Wieder HA, Beer AJ, Lordick F et al (2005) Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46 (12):2029-2034 (Pubitemid 46657450)
41. Denecke T, Rau B, Hoffmann KT et al (2005) Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: Is there a benefit in using functional imaging? Eur Radiol 15(8):1658-1666 (Pubitemid 41102362)
42. Kim NK, Baik SH, Min BS et al (2007) A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. Int J Radiat Oncol Biol Phys 67 (1):204-210 (Pubitemid 44959490)
43. Beets-Tan RG, Beets GL (2004) Rectal cancer: Review with emphasis on MR imaging. Radiology 232(2):335-346 (Pubitemid 38971269)
44. Wallengren NO, Holtas S, Andren-Sandberg A, Jonsson E, Kristoffersson DT, McGill S (2000) Rectal carcinoma: Double-contrast MR imaging for preoperative staging. Radiology 215(1):108-114 (Pubitemid 30190518)
45. Kuo LJ, Chern MC, Tsou MH et al (2005) Interpretation of magnetic resonance imaging for locally advanced rectal carcinoma after preoperative chemoradiation therapy. Dis Colon Rectum 48(1):23-28
46. Suppiah A, Hunter IA, Cowley J et al (2009) Magnetic resonance imaging accuracy in assessing tumour down-staging following chemoradiation in rectal cancer. Colorectal Dis 11(3):249-253